It is an exciting time in Alzheimer's research and treatment. For the first time, we have treatments that can change the course of Alzheimer’s disease. Lecanemab (Leqembi) received traditional approval as a treatment for early Alzheimer's from the FDA in 2023. This drug slows progression of the disease when taken in the early stages of Alzheimer's, giving individuals more time to participate in daily life and live independently. And there are more treatments like this in clinical trials now.
The Alzheimer’s Association’s work is far from done. The Alzheimer's Association is the largest nonprofit funder of Alzheimer's research, currently investing over $320 million in more than 1,000 active best-of-field projects in 54 countries.
We won’t rest until everyone living with Alzheimer’s and all other dementia — at any stage — can get the treatment, care and support they need and deserve.
Fund master's-level 1:1 support for people living with the disease and their families.
The Alzheimer’s Association 24/7 Helpline receives nearly 250,000 calls each year. It doesn't have to be a crisis. We're here to talk at 800.272.3900.
Fund critical research.
The Alzheimer's Association is the world's largest nonprofit funder of Alzheimer's research. Currently, investing over $320 million in more than 1,000 active best-of-field projects in 54 countries.
Fund fighting for health equity.
Black Americans, Hispanic/Latine Americans and women are disproportionally impacted by Alzheimer's disease. Join us in fighting for representation in research and access to diagnosis and treatment.
Families facing Alzheimer’s and all other dementia need us now more than ever — and with your help, we can be there for them. Together, we can end Alzheimer’s disease.
Thank you!
My Progress
Thank you for helping advance Alzheimer's support, care and research.
100
I have raised
1000
My Goal
My Achievements
Self-Donor
T-shirt
Storyteller